{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:19:19Z","timestamp":1744085959684},"reference-count":136,"publisher":"IntechOpen","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.5772\/intechopen.85222","type":"book-chapter","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T08:41:55Z","timestamp":1555490515000},"source":"Crossref","is-referenced-by-count":1,"title":["Epstein-Barr Virus in Multiple Sclerosis"],"prefix":"10.5772","author":[{"given":"Gulfaraz","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asma","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3774","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Compston A, Coles A.\u00a0Multiple sclerosis. Lancet. 2008;372:1502-1517","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Baranzini SE, Oksenberg JR.\u00a0The genetics of multiple sclerosis: From 0 to 200\u00a0in 50 years. Trends in Genetics. 2017;33:960-970","DOI":"10.1016\/j.tig.2017.09.004"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Gourraud P-A, Harbo HF, Hauser SL, et\u00a0al. The genetics of multiple sclerosis: An up-to-date review. Immunological Reviews. 2012;248:87-103","DOI":"10.1111\/j.1600-065X.2012.01134.x"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Dilokthornsakul P, Valuck RJ, Nair\u00a0KV, et\u00a0al. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014-1021","DOI":"10.1212\/WNL.0000000000002469"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Rosati G.\u00a0The prevalence of multiple sclerosis in the world: An update. Neurological Sciences. 2001;22:117-139","DOI":"10.1007\/s100720170011"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Wallin MT, Culpepper WJ, Coffman\u00a0P, et\u00a0al. The gulf war era multiple sclerosis cohort: Age and incidence rates by race, sex and service. Brain. 2012;135:1778-1785","DOI":"10.1093\/brain\/aws099"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Langer-Gould A, Brara SM, Beaber\u00a0BE, et\u00a0al. Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology. 2013;80:1734-1739","DOI":"10.1212\/WNL.0b013e3182918cc2"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Compston A.\u00a0The genetic epidemiology of multiple sclerosis. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 1999;354:1623-1634","DOI":"10.1098\/rstb.1999.0507"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Hansen T, Skytthe A, Stenager E, et\u00a0al. Risk for multiple sclerosis in dizygotic and monozygotic twins. Multiple Sclerosis. 2005;11:500-503","DOI":"10.1191\/1352458505ms1202oa"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Wade BJ.\u00a0Spatial analysis of global prevalence of multiple sclerosis suggests need for an updated prevalence scale. Multiple Sclerosis International. 2014;2014:124578","DOI":"10.1155\/2014\/124578"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Melcon MO, Correale J, Melcon\u00a0CM. Is it time for a new global classification\u00a0of multiple sclerosis? Journal of the Neurological Sciences. 2014;344:171-181","DOI":"10.1016\/j.jns.2014.06.051"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Koch-Henriksen N, S\u00f8rensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology. 2010;9:520-532","DOI":"10.1016\/S1474-4422(10)70064-8"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Berg-Hansen P, Celius EG.\u00a0Socio-economic factors and immigrant population studies of multiple sclerosis. Acta Neurologica Scandinavica. 2015;132:37-41","DOI":"10.1111\/ane.12429"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Nasr Z, Majed M, Rostami A, et\u00a0al. Prevalence of multiple sclerosis in Iranian emigrants: Review of the evidence. Neurological Sciences. 2016;37:1759-1763","DOI":"10.1007\/s10072-016-2641-7"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Ahlgren C, Lycke J, Od\u00e9n A, et\u00a0al. High risk of MS in Iranian immigrants in Gothenburg, Sweden. Multiple Sclerosis. 2010;16:1079-1082","DOI":"10.1177\/1352458510376777"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Berg-Hansen P, Moen SM, Sandvik\u00a0L, et\u00a0al. Prevalence of multiple sclerosis among immigrants in Norway. Multiple Sclerosis. 2015;21:695-702","DOI":"10.1177\/1352458514554055"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Milo R, Kahana E.\u00a0Multiple sclerosis: Geoepidemiology, genetics and the environment. Autoimmunity Reviews. 2010;9:A387-A394","DOI":"10.1016\/j.autrev.2009.11.010"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"McLeod JG, Hammond SR, Kurtzke JF.\u00a0Migration and multiple sclerosis in immigrants to Australia from United Kingdom and Ireland: A reassessment. I.\u00a0Risk of MS by age at immigration. Journal of Neurology. 2011;258:1140-1149","DOI":"10.1007\/s00415-010-5898-4"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Annals of Neurology. 2007;61:504-513","DOI":"10.1002\/ana.21141"},{"key":"ref=20","unstructured":"Ascherio A, Munger KL, L\u00fcnemann\u00a0JD. The initiation and prevention of multiple sclerosis. Nature Reviews. Neurology. 2012;8:602-612"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Correale J, Gait\u00e1n MI.\u00a0Multiple sclerosis and environmental factors: The role of vitamin D, parasites, and Epstein-Barr virus infection. Acta Neurologica Scandinavica. 2015;132:46-55","DOI":"10.1111\/ane.12431"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Reich DS, Lucchinetti CF, Calabresi\u00a0PA.\u00a0Multiple sclerosis. The New England Journal of Medicine. 2018;378:169-180","DOI":"10.1056\/NEJMra1401483"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Belbasis L, Bellou V, Evangelou\u00a0E, et\u00a0al. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. Lancet Neurology. 2015;14:263-273","DOI":"10.1016\/S1474-4422(14)70267-4"},{"key":"ref=24","unstructured":"Wallin MT, Heltberg A, Kurtzke JF. Multiple sclerosis in the Faroe Islands. 8. Notifiable diseases. Acta Neurologica Scandinavica. 2010;122:102-109"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Hughes A-M, Lucas RM, McMichael\u00a0AJ, et\u00a0al. Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially. Clinical and Experimental Immunology. 2013;172:466-474","DOI":"10.1111\/cei.12077"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Gustavsen MW, Page CM, Moen\u00a0SM, et\u00a0al. Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study. BMC Neurology. 2014;14:196","DOI":"10.1186\/s12883-014-0196-x"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Pedrini MJF, Seewann A, Bennett\u00a0KA, et\u00a0al. Helicobacter pylori infection as a protective factor against multiple sclerosis risk in females. Journal of Neurology, Neurosurgery, and Psychiatry. 2015;86:603-607","DOI":"10.1136\/jnnp-2014-309495"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Eskandarieh S, Heydarpour P, Minagar A, et\u00a0al. Multiple sclerosis epidemiology in East Asia, South East Asia and South Asia: A systematic review. Neuroepidemiology. 2016;46:209-221","DOI":"10.1159\/000444019"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Wendel-Haga M, Celius EG.\u00a0Is the hygiene hypothesis relevant for the risk of multiple sclerosis? Acta Neurologica Scandinavica. 2017;136(Suppl 201):26-30","DOI":"10.1111\/ane.12844"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Libbey JE, Cusick MF, Fujinami RS. Role of pathogens in multiple sclerosis. International Reviews of Immunology. 2014;33:266-283","DOI":"10.3109\/08830185.2013.823422"},{"key":"ref=31","unstructured":"Lim Y, Romano N, Colin N, et\u00a0al. Intestinal parasitic infections amongst orang Asli (indigenous) in Malaysia: Has socioeconomic development alleviated the problem? Tropical Biomedicine. 2009;26:110-122"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Ascherio A, Munger KL. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: Epstein-Barr virus and multiple sclerosis: Epidemiological evidence. Clinical and Experimental Immunology. 2010;160:120-124","DOI":"10.1111\/j.1365-2249.2010.04121.x"},{"key":"ref=33","unstructured":"Young LS, Yap LF, Murray PG. Epstein-Barr virus: More than 50 years old and still providing surprises. Nature Reviews. Cancer. 2016;16:789-802"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Dunmire SK, Verghese PS, Balfour\u00a0HH. Primary Epstein-Barr virus infection. Journal of Clinical Virology. 2018;102:84-92","DOI":"10.1016\/j.jcv.2018.03.001"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Niedobitek G, Meru N, Delecluse\u00a0HJ. Epstein-Barr virus infection and human malignancies. International Journal of Experimental Pathology. 2001;82:149-170","DOI":"10.1111\/j.1365-2613.2001.iep190.x"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Khan G, Hashim MJ.\u00a0Global burden\u00a0of deaths from Epstein-Barr virus attributable malignancies 1990-2010. Infectious Agents and Cancer. 2014;9:38","DOI":"10.1186\/1750-9378-9-38"},{"key":"ref=37","unstructured":"Young LS, Rickinson AB.\u00a0Epstein-Barr virus: 40 years on. Nature Reviews. Cancer. 2004;4:757-768"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson DA, Miyashita\u00a0EM, Khan G.\u00a0Epstein-Barr virus and the B cell: That\u2019s all it takes. Trends in Microbiology. 1996;4:204-208","DOI":"10.1016\/S0966-842X(96)90020-7"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Babcock GJ, Decker LL, Volk M, et\u00a0al. EBV persistence in memory B cells in\u00a0vivo. Immunity. 1998;9:395-404","DOI":"10.1016\/S1074-7613(00)80622-6"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Khan G, Miyashita EM, Yang B, et\u00a0al. Is EBV persistence in\u00a0vivo a model for B cell homeostasis? Immunity. 1996;5:173-179","DOI":"10.1016\/S1074-7613(00)80493-8"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Brink AA, Dukers DF, van den Brule AJ, et\u00a0al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. Journal of Clinical Pathology. 1997;50:911-918","DOI":"10.1136\/jcp.50.11.911"},{"key":"ref=42","doi-asserted-by":"crossref","unstructured":"Tierney RJ, Steven N, Young LS, et\u00a0al. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene\u00a0transcription during primary\u00a0infection and in the carrier state. Journal\u00a0of Virology. 1994;68:7374-7385","DOI":"10.1128\/JVI.68.11.7374-7385.1994"},{"key":"ref=43","doi-asserted-by":"crossref","unstructured":"Thorley-Lawson DA.\u00a0EBV persistence\u2013Introducing the virus. Current Topics in Microbiology and Immunology. 2015;390:151-209","DOI":"10.1007\/978-3-319-22822-8_8"},{"key":"ref=44","unstructured":"Skalsky RL, Cullen BR.\u00a0EBV noncoding RNAs. Current Topics in Microbiology and Immunology. 2015;391:181-217"},{"key":"ref=45","doi-asserted-by":"crossref","unstructured":"Kaul V, Weinberg KI, Boyd SD, et\u00a0al. Dynamics of viral and host immune cell microRNA expression during acute infectious mononucleosis. Frontiers in Microbiology. 2017;8:2666","DOI":"10.3389\/fmicb.2017.02666"},{"key":"ref=46","doi-asserted-by":"crossref","unstructured":"M\u00fcnz C.\u00a0Epstein Barr virus\u2013A tumor virus that needs cytotoxic lymphocytes to persist asymptomatically. Current Opinion in Virology. 2016;20:34-39","DOI":"10.1016\/j.coviro.2016.08.010"},{"key":"ref=47","doi-asserted-by":"crossref","unstructured":"Sumaya CV, Myers LW, Ellison\u00a0GW. Epstein-Barr virus antibodies in multiple sclerosis. Archives of Neurology. 1980;37:94-96","DOI":"10.1001\/archneur.1980.00500510052009"},{"key":"ref=48","doi-asserted-by":"crossref","unstructured":"Sumaya CV, Myers LW, Ellison GW, et\u00a0al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Annals of Neurology. 1985;17:371-377","DOI":"10.1002\/ana.410170412"},{"key":"ref=49","doi-asserted-by":"crossref","unstructured":"Pohl D, Krone B, Rostasy K, et\u00a0al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006;67:2063-2065","DOI":"10.1212\/01.wnl.0000247665.94088.8d"},{"key":"ref=50","doi-asserted-by":"crossref","unstructured":"Banwell B, Krupp L, Kennedy\u00a0J, et\u00a0al. Clinical features and viral serologies in children with multiple sclerosis: A multinational observational\u00a0study. Lancet Neurology. 2007;6:773-781","DOI":"10.1016\/S1474-4422(07)70196-5"},{"key":"ref=51","doi-asserted-by":"crossref","unstructured":"Alotaibi S, Kennedy J, Tellier R, et\u00a0al. Epstein-Barr virus in pediatric multiple sclerosis. JAMA. 2004;291:1875-1879","DOI":"10.1001\/jama.291.15.1875"},{"key":"ref=52","doi-asserted-by":"crossref","unstructured":"Waubant E, Mowry EM, Krupp L, et\u00a0al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology. 2011;76:1989-1995","DOI":"10.1212\/WNL.0b013e31821e552a"},{"key":"ref=53","doi-asserted-by":"crossref","unstructured":"Ascherio A, Munch M.\u00a0Epstein-Barr virus and multiple sclerosis. Epidemiology. 2000;11:220-224","DOI":"10.1097\/00001648-200003000-00023"},{"key":"ref=54","doi-asserted-by":"crossref","unstructured":"Levin LI, Munger KL, O\u2019Reilly\u00a0EJ, et\u00a0al. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Annals of Neurology. 2010;67:824-830","DOI":"10.1002\/ana.21978"},{"key":"ref=55","unstructured":"Warner HB, Carp RI.\u00a0Multiple sclerosis and Epstein-Barr virus. Lancet. 1981;2:1290"},{"key":"ref=56","doi-asserted-by":"crossref","unstructured":"Sawyer RN, Evans AS, Niederman\u00a0JC, et\u00a0al. Prospective studies of a group of Yale University freshmen. I.\u00a0Occurrence of infectious mononucleosis. The Journal of Infectious Diseases. 1971;123:263-270","DOI":"10.1093\/infdis\/123.3.263"},{"key":"ref=57","doi-asserted-by":"crossref","unstructured":"Macsween KF, Higgins CD, McAulay\u00a0KA, et\u00a0al. Infectious mononucleosis in university students in the United Kingdom: Evaluation of the clinical features and consequences of the disease. Clinical Infectious Diseases. 2010;50:699-706","DOI":"10.1086\/650456"},{"key":"ref=58","doi-asserted-by":"crossref","unstructured":"Lucas RM, Ponsonby A-L, Dear\u00a0K, et\u00a0al. Current and past Epstein-Barr virus infection in risk of initial CNS demyelination. Neurology. 2011;77:371-379","DOI":"10.1212\/WNL.0b013e318227062a"},{"key":"ref=59","doi-asserted-by":"crossref","unstructured":"Thacker EL, Mirzaei F, Ascherio\u00a0A. Infectious mononucleosis and risk for multiple sclerosis: A meta-analysis. Annals of Neurology. 2006;59:499-503","DOI":"10.1002\/ana.20820"},{"key":"ref=60","doi-asserted-by":"crossref","unstructured":"Nielsen TR, Rostgaard K, Nielsen\u00a0NM, et\u00a0al. Multiple sclerosis after infectious mononucleosis. Archives of Neurology. 2007;64:72-75","DOI":"10.1001\/archneur.64.1.72"},{"key":"ref=61","doi-asserted-by":"crossref","unstructured":"Haahr S, Koch-Henriksen N, M\u00f8ller-Larsen A, et\u00a0al. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: A historical prospective study. Multiple Sclerosis. 1995;1:73-77","DOI":"10.1177\/135245859500100203"},{"key":"ref=62","doi-asserted-by":"crossref","unstructured":"Levin LI, Munger KL, Rubertone\u00a0MV, et\u00a0al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA. 2005;293:2496-2500","DOI":"10.1001\/jama.293.20.2496"},{"key":"ref=63","doi-asserted-by":"crossref","unstructured":"Sundstr\u00f6m P, Juto P, Wadell G, et\u00a0al. An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology. 2004;62:2277-2282","DOI":"10.1212\/01.WNL.0000130496.51156.D7"},{"key":"ref=64","doi-asserted-by":"crossref","unstructured":"DeLorenze GN, Munger KL, Lennette ET, et\u00a0al. Epstein-Barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up. Archives of Neurology. 2006;63:839-844","DOI":"10.1001\/archneur.63.6.noc50328"},{"key":"ref=65","doi-asserted-by":"crossref","unstructured":"Comabella M, Montalban X, Horga\u00a0A, et\u00a0al. Antiviral immune response in patients with multiple sclerosis and healthy siblings. Multiple Sclerosis. 2010;16:355-358","DOI":"10.1177\/1352458509357066"},{"key":"ref=66","doi-asserted-by":"crossref","unstructured":"L\u00fcnemann JD, Tintor\u00e9 M, Messmer\u00a0B, et\u00a0al. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Annals of Neurology. 2010;67:159-169","DOI":"10.1002\/ana.21886"},{"key":"ref=67","doi-asserted-by":"crossref","unstructured":"Schlemm L, Giess RM, Rasche L, et\u00a0al. Fine specificity of the antibody response to Epstein-Barr nuclear antigen-2 and other Epstein-Barr virus proteins in patients with clinically isolated syndrome: A peptide microarray-based case-control study. Journal of Neuroimmunology. 2016;297:56-62","DOI":"10.1016\/j.jneuroim.2016.05.012"},{"key":"ref=68","doi-asserted-by":"crossref","unstructured":"Ascherio A, Munger KL, Lennette ET, et\u00a0al. Epstein-Barr virus antibodies and risk of multiple sclerosis: A prospective study. JAMA. 2001;286:3083-3088","DOI":"10.1001\/jama.286.24.3083"},{"key":"ref=69","doi-asserted-by":"crossref","unstructured":"Sundqvist E, Sundstr\u00f6m P, Lind\u00e9n M, et\u00a0al. Epstein-Barr virus and multiple sclerosis: Interaction with HLA.\u00a0Genes and Immunity. 2012;13:14-20","DOI":"10.1038\/gene.2011.42"},{"key":"ref=70","doi-asserted-by":"crossref","unstructured":"Rubicz R, Yolken R, Drigalenko\u00a0E, et\u00a0al. A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein-Barr virus nuclear antigen 1 (EBNA-1). PLoS Genetics. 2013;9:e1003147","DOI":"10.1371\/journal.pgen.1003147"},{"key":"ref=71","doi-asserted-by":"crossref","unstructured":"Farrell RA, Antony D, Wall GR, et\u00a0al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.\u00a0Neurology. 2009;73:32-38","DOI":"10.1212\/WNL.0b013e3181aa29fe"},{"key":"ref=72","doi-asserted-by":"crossref","unstructured":"Almohmeed YH, Avenell A, Aucott\u00a0L, et\u00a0al. Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. PLoS One. 2013;8:e61110","DOI":"10.1371\/journal.pone.0061110"},{"key":"ref=73","doi-asserted-by":"crossref","unstructured":"Zivadinov R, Cerza N, Hagemeier\u00a0J, et\u00a0al. Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.\u00a0Neurology Neuroimmunology & Neuroinflammation. 2016;3:e190","DOI":"10.1212\/NXI.0000000000000190"},{"key":"ref=74","doi-asserted-by":"crossref","unstructured":"Wandinger K, Jabs W, Siekhaus\u00a0A, et\u00a0al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS.\u00a0Neurology. 2000;55:178-184","DOI":"10.1212\/WNL.55.2.178"},{"key":"ref=75","doi-asserted-by":"crossref","unstructured":"Buljevac D, van Doornum GJJ, Flach\u00a0HZ, et\u00a0al. Epstein-Barr virus and disease activity in multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. 2005;76:1377-1381","DOI":"10.1136\/jnnp.2004.048504"},{"key":"ref=76","doi-asserted-by":"crossref","unstructured":"Gie\u00df RM, Pfuhl C, Behrens JR, et\u00a0al. Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS One. 2017;12:e0175279","DOI":"10.1371\/journal.pone.0175279"},{"key":"ref=77","doi-asserted-by":"crossref","unstructured":"Kakalacheva K, Regenass\u00a0S, Wiesmayr S, et\u00a0al. Infectious mononucleosis triggers generation of IgG auto-antibodies against native myelin oligodendrocyte glycoprotein. Viruses. 2016;8. DOI: 10.3390\/v8020051","DOI":"10.3390\/v8020051"},{"key":"ref=78","doi-asserted-by":"crossref","unstructured":"Wergeland S, Myhr K-M, L\u00f8ken-Amsrud KI, et\u00a0al. Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients. European Journal of Neurology. 2016;23:1064-1070","DOI":"10.1111\/ene.12986"},{"key":"ref=79","doi-asserted-by":"crossref","unstructured":"Rolf L, Muris A-H, Mathias A, et\u00a0al. Exploring the effect of vitamin D3 supplementation on the anti-EBV antibody response in relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2018;24:1280-1287","DOI":"10.1177\/1352458517722646"},{"key":"ref=80","doi-asserted-by":"crossref","unstructured":"Fraser KB, Haire M, Millar JH, et\u00a0al. Increased tendency to spontaneous in-vitro lymphocyte transformation in clinically active multiple sclerosis. Lancet. 1979;2:175-176","DOI":"10.1016\/S0140-6736(79)90643-3"},{"key":"ref=81","doi-asserted-by":"crossref","unstructured":"Jilek S, Schluep M, Harari A, et\u00a0al. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. Journal of Immunology. 2012;188:4671-4680","DOI":"10.4049\/jimmunol.1103100"},{"key":"ref=82","doi-asserted-by":"crossref","unstructured":"Angelini DF, Serafini B, Piras E, et\u00a0al. Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathogens. 2013;9:e1003220","DOI":"10.1371\/journal.ppat.1003220"},{"key":"ref=83","doi-asserted-by":"crossref","unstructured":"Pender MP, Csurhes PA, Burrows\u00a0JM, et\u00a0al. Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clinical & Translational Immunology. 2017;6:e126","DOI":"10.1038\/cti.2016.87"},{"key":"ref=84","doi-asserted-by":"crossref","unstructured":"Cencioni MT, Magliozzi R, Nicholas\u00a0R, et\u00a0al. Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. Immunology. 2017;152:660-676","DOI":"10.1111\/imm.12808"},{"key":"ref=85","doi-asserted-by":"crossref","unstructured":"Day CL, Kaufmann DE, Kiepiela P, et\u00a0al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443:350-354","DOI":"10.1038\/nature05115"},{"key":"ref=86","doi-asserted-by":"crossref","unstructured":"Barber DL, Wherry EJ, Masopust D, et\u00a0al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682-687","DOI":"10.1038\/nature04444"},{"key":"ref=87","doi-asserted-by":"crossref","unstructured":"Wherry EJ.\u00a0T cell exhaustion. Nature Immunology. 2011;12:492-499","DOI":"10.1038\/ni.2035"},{"key":"ref=88","doi-asserted-by":"crossref","unstructured":"Wagner H-J, Munger KL, Ascherio\u00a0A. Plasma viral load of Epstein-Barr virus and risk of multiple sclerosis. European Journal of Neurology. 2004;11:833-834","DOI":"10.1111\/j.1468-1331.2004.00871.x"},{"key":"ref=89","doi-asserted-by":"crossref","unstructured":"Agostini S, Mancuso R, Guerini FR, et\u00a0al. HLA alleles modulate EBV viral load in multiple sclerosis. Journal of Translational Medicine. 2018;16:80","DOI":"10.1186\/s12967-018-1450-6"},{"key":"ref=90","doi-asserted-by":"crossref","unstructured":"Lindsey JW, Hatfield LM, Crawford\u00a0MP, et\u00a0al. Quantitative PCR for Epstein-Barr virus DNA and RNA in multiple sclerosis. Multiple Sclerosis. 2009;15:153-158","DOI":"10.1177\/1352458508097920"},{"key":"ref=91","doi-asserted-by":"crossref","unstructured":"Holden DW, Gold J, Hawkes CH, et\u00a0al. Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts. Multiple Sclerosis and Related Disorders. 2018;25:197-199","DOI":"10.1016\/j.msard.2018.07.041"},{"key":"ref=92","doi-asserted-by":"crossref","unstructured":"Marrie RA, Elliott L, Marriott J, et\u00a0al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology. 2014;83:929-937","DOI":"10.1212\/WNL.0000000000000753"},{"key":"ref=93","doi-asserted-by":"crossref","unstructured":"Glenn JD, Smith MD, Xue P, et\u00a0al. CNS-targeted autoimmunity leads to increased influenza mortality in mice. Journal of Experimental Medicine. 2017;214:297-307","DOI":"10.1084\/jem.20160517"},{"key":"ref=94","doi-asserted-by":"crossref","unstructured":"T\u00f8rring C, Andreasen C, Gehr\u00a0N, et\u00a0al. Higher incidence of Epstein-Barr virus-induced lymphocyte transformation in multiple sclerosis. Acta Neurologica Scandinavica. 2014;130:90-96","DOI":"10.1111\/ane.12249"},{"key":"ref=95","doi-asserted-by":"crossref","unstructured":"Lossius A, Johansen JN, Vartdal F, et\u00a0al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. European Journal of Immunology. 2014;44:3439-3452","DOI":"10.1002\/eji.201444662"},{"key":"ref=96","doi-asserted-by":"crossref","unstructured":"van Nierop GP, Mautner J, Mitterreiter JG, et\u00a0al. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins. Multiple Sclerosis. 2016;22:279-291","DOI":"10.1177\/1352458515588581"},{"key":"ref=97","doi-asserted-by":"crossref","unstructured":"van Nierop GP, Janssen M, Mitterreiter JG, et\u00a0al. Intrathecal CD4(+) and CD8(+) T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients. European Journal of Immunology. 2016;46:347-353","DOI":"10.1002\/eji.201545921"},{"key":"ref=98","doi-asserted-by":"crossref","unstructured":"Planas R, Santos R, Tomas-Ojer P, et\u00a0al. GDP-l-fucose synthase is a CD4+ T cell\u2013specific autoantigen in DRB3*02:02 patients with multiple sclerosis. Science Translational Medicine. 2018;10:eaat4301","DOI":"10.1126\/scitranslmed.aat4301"},{"key":"ref=99","doi-asserted-by":"crossref","unstructured":"Wekerle H, Hohlfeld R.\u00a0Molecular mimicry in multiple sclerosis. The New England Journal of Medicine. 2003;349:185-186","DOI":"10.1056\/NEJMcibr035136"},{"key":"ref=100","unstructured":"Wherry EJ, Kurachi M.\u00a0Molecular and cellular insights into T cell exhaustion. Nature Reviews. Immunology. 2015;15:486-499"},{"key":"ref=101","doi-asserted-by":"crossref","unstructured":"Geginat J, Paroni M, Pagani M, et\u00a0al. The enigmatic role of viruses in multiple sclerosis: Molecular mimicry or disturbed immune surveillance? Trends in Immunology. 2017;38:498-512","DOI":"10.1016\/j.it.2017.04.006"},{"key":"ref=102","doi-asserted-by":"crossref","unstructured":"L\u00fcnemann JD, Jelci\u0107 I, Roberts\u00a0S, et\u00a0al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. The Journal of Experimental Medicine. 2008;205:1763-1773","DOI":"10.1084\/jem.20072397"},{"key":"ref=103","doi-asserted-by":"crossref","unstructured":"Cepok S, Zhou D, Srivastava R, et\u00a0al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. The Journal of Clinical Investigation. 2005;115:1352-1360","DOI":"10.1172\/JCI200523661"},{"key":"ref=104","doi-asserted-by":"crossref","unstructured":"L\u00fcnemann JD, Edwards N, Muraro PA, et\u00a0al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain. 2006;129:1493-1506","DOI":"10.1093\/brain\/awl067"},{"key":"ref=105","doi-asserted-by":"crossref","unstructured":"Hilton DA, Love S, Fletcher A, et\u00a0al. Absence of Epstein-Barr virus RNA in multiple sclerosis as assessed by in situ hybridisation. Journal of Neurology, Neurosurgery, and Psychiatry. 1994;57:975-976","DOI":"10.1136\/jnnp.57.8.975"},{"key":"ref=106","doi-asserted-by":"crossref","unstructured":"Opsahl ML, Kennedy PGE.\u00a0An attempt to investigate the presence of Epstein Barr virus in multiple sclerosis and normal control brain tissue. Journal of Neurology. 2007;254:425-430","DOI":"10.1007\/s00415-006-0316-7"},{"key":"ref=107","doi-asserted-by":"crossref","unstructured":"Serafini B, Rosicarelli B, Franciotta\u00a0D, et\u00a0al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. The Journal of Experimental Medicine. 2007;204:2899-2912","DOI":"10.1084\/jem.20071030"},{"key":"ref=108","doi-asserted-by":"crossref","unstructured":"Tzartos JS, Khan G, Vossenkamper\u00a0A, et\u00a0al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012;78:15-23","DOI":"10.1212\/WNL.0b013e31823ed057"},{"key":"ref=109","doi-asserted-by":"crossref","unstructured":"Magliozzi R, Serafini B, Rosicarelli\u00a0B, et\u00a0al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. Journal of Neuropathology and Experimental Neurology. 2013;72:29-41","DOI":"10.1097\/NEN.0b013e31827bfc62"},{"key":"ref=110","doi-asserted-by":"crossref","unstructured":"Willis SN, Stadelmann C, Rodig\u00a0SJ, et\u00a0al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132:3318-3328","DOI":"10.1093\/brain\/awp200"},{"key":"ref=111","doi-asserted-by":"crossref","unstructured":"Peferoen LAN, Lamers F, Lodder\u00a0LNR, et\u00a0al. Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain. 2010;133:e137","DOI":"10.1093\/brain\/awp296"},{"key":"ref=112","doi-asserted-by":"crossref","unstructured":"Sargsyan SA, Shearer AJ, Ritchie\u00a0AM, et\u00a0al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74:1127-1135","DOI":"10.1212\/WNL.0b013e3181d865a1"},{"key":"ref=113","doi-asserted-by":"crossref","unstructured":"Lassmann H, Niedobitek G, Aloisi F, et\u00a0al. Epstein-Barr virus in the multiple sclerosis brain: A controversial issue\u2013Report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria. Brain. 2011;134:2772-2786","DOI":"10.1093\/brain\/awr197"},{"key":"ref=114","doi-asserted-by":"crossref","unstructured":"Aloisi F, Serafini B, Magliozzi R, et\u00a0al. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: What you find depends on how and where you look. Brain. 2010;133:e157","DOI":"10.1093\/brain\/awq223"},{"key":"ref=115","doi-asserted-by":"crossref","unstructured":"Hassani A, Corboy JR, Al-Salam S, et\u00a0al. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PLoS One. 2018;13:e0192109","DOI":"10.1371\/journal.pone.0192109"},{"key":"ref=116","doi-asserted-by":"crossref","unstructured":"Naegelin Y, Naegelin P, von\u00a0Felten\u00a0S, et\u00a0al. Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis. JAMA Neurology. 2019. DOI: 10.1001\/jamaneurol.2018.4239","DOI":"10.1001\/jamaneurol.2018.4239"},{"key":"ref=117","doi-asserted-by":"crossref","unstructured":"Baker D, Marta M, Pryce G, et\u00a0al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. eBioMedicine. 2017;16:41-50","DOI":"10.1016\/j.ebiom.2017.01.042"},{"key":"ref=118","doi-asserted-by":"crossref","unstructured":"Jelcic I, Al Nimer F, Wang J, et\u00a0al. Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis. Cell. 2018;175:85-100. e23","DOI":"10.1016\/j.cell.2018.08.011"},{"key":"ref=119","doi-asserted-by":"crossref","unstructured":"Michel L, Touil H, Pikor\u00a0NB, et\u00a0al. B Cells in the multiple sclerosis central nervous system: Trafficking and contribution to CNS-compartmentalized Inflammation. Frontiers in Immunology. 2015;6. DOI: 10.3389\/fimmu.2015.00636","DOI":"10.3389\/fimmu.2015.00636"},{"key":"ref=120","doi-asserted-by":"crossref","unstructured":"Blauth K, Owens GP, Bennett\u00a0JL.\u00a0The ins and outs of B cells in multiple sclerosis. Frontiers in Immunology. 2015;6. DOI: 10.3389\/fimmu.2015.00565","DOI":"10.3389\/fimmu.2015.00565"},{"key":"ref=121","doi-asserted-by":"crossref","unstructured":"Laichalk LL, Thorley-Lawson DA. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus In vivo. Journal of Virology. 2005;79:1296-1307","DOI":"10.1128\/JVI.79.2.1296-1307.2005"},{"key":"ref=122","doi-asserted-by":"crossref","unstructured":"Moreno MA, Or-Geva N, Aftab\u00a0BT, et\u00a0al. Molecular signature of Epstein-Barr virus infection in MS brain lesions. Neurology\u2013Neuroimmunology Neuroinflammation. 2018;5:e466","DOI":"10.1212\/NXI.0000000000000466"},{"key":"ref=123","doi-asserted-by":"crossref","unstructured":"Gasque P, Chan P, Mauger C, et\u00a0al. Identification and characterization of complement C3 receptors on human astrocytes. The Journal of Immunology. 1996;156:2247-2255","DOI":"10.4049\/jimmunol.156.6.2247"},{"key":"ref=124","doi-asserted-by":"crossref","unstructured":"Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathologica. 2010;119:7-35","DOI":"10.1007\/s00401-009-0619-8"},{"key":"ref=125","doi-asserted-by":"crossref","unstructured":"Liddelow SA, Barres BA.\u00a0Reactive astrocytes: Production, function, and therapeutic potential. Immunity. 2017;46:957-967","DOI":"10.1016\/j.immuni.2017.06.006"},{"key":"ref=126","doi-asserted-by":"crossref","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE, et\u00a0al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017;541:481-487","DOI":"10.1038\/nature21029"},{"key":"ref=127","doi-asserted-by":"crossref","unstructured":"Sankowski R, Mader S, Vald\u00e9s-Ferrer SI.\u00a0Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Frontiers in Cellular Neuroscience. 2015;9. DOI: 10.3389\/fncel.2015.00028","DOI":"10.3389\/fncel.2015.00028"},{"key":"ref=128","unstructured":"Aloisi F, Pujol-Borrell R.\u00a0Lymphoid neogenesis in chronic inflammatory diseases. Nature Reviews. Immunology. 2006;6:205-217"},{"key":"ref=129","doi-asserted-by":"crossref","unstructured":"Pikor NB, Prat A, Bar-Or A, et\u00a0al. Meningeal tertiary lymphoid tissues and multiple sclerosis: A gathering place for diverse types of immune cells during CNS autoimmunity. Frontiers in Immunology. 2016;6. DOI: 10.3389\/fimmu.2015.00657","DOI":"10.3389\/fimmu.2015.00657"},{"key":"ref=130","doi-asserted-by":"crossref","unstructured":"Corcione A, Casazza S, Ferretti\u00a0E, et\u00a0al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. PNAS. 2004;101:11064-11069","DOI":"10.1073\/pnas.0402455101"},{"key":"ref=131","doi-asserted-by":"crossref","unstructured":"Ahmed W, Tariq S, Khan G. Tracking EBV-encoded RNAs (EBERs) from the nucleus to the excreted exosomes of B-lymphocytes. Scientific Reports. 2018;8:15438","DOI":"10.1038\/s41598-018-33758-4"},{"key":"ref=132","doi-asserted-by":"crossref","unstructured":"Moutsianas L, Jostins L, Beecham AH, et\u00a0al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nature Genetics. 2015;47:1107-1113","DOI":"10.1038\/ng.3395"},{"key":"ref=133","doi-asserted-by":"crossref","unstructured":"Hanisch U-K, Kettenmann H. Microglia: Active sensor and versatile effector cells in the normal and pathologic brain. Nature Neuroscience. 2007;10:1387-1394","DOI":"10.1038\/nn1997"},{"key":"ref=134","doi-asserted-by":"crossref","unstructured":"Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends in Molecular Medicine. 2018;25:112-123. DOI: 10.1016\/j.molmed.2018.11.005","DOI":"10.1016\/j.molmed.2018.11.005"},{"key":"ref=135","doi-asserted-by":"crossref","unstructured":"Pender MP, Csurhes PA, Smith C, et\u00a0al. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight. 2018;3. DOI: 10.1172\/jci.insight.124714","DOI":"10.1172\/jci.insight.124714"},{"key":"ref=136","doi-asserted-by":"crossref","unstructured":"Cohen JI.\u00a0Epstein-Barr virus vaccines. Clinical & Translational Immunology. 2015;4:e32","DOI":"10.1038\/cti.2014.27"}],"container-title":["Multiple Sclerosis [Working Title]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.intechopen.com\/download\/pdf\/66148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T20:35:22Z","timestamp":1694810122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.intechopen.com\/online-first\/epstein-barr-virus-in-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":136,"URL":"https:\/\/doi.org\/10.5772\/intechopen.85222","relation":{},"subject":[],"published":{"date-parts":[[2019,4,10]]}}}